bioAffinity Technologies, Inc. 8-K

What Happened

• On April 14, 2026, bioAffinity Technologies, Inc. (the Company) filed a Form 8-K (Item 8.01) and issued a press release describing a new clinical case study. The case study reports how CyPath® Lung, the Company’s noninvasive sputum‑based diagnostic test, helped determine next steps for a high‑risk patient with a suspicious pulmonary nodule where imaging and risk models suggested a high likelihood of cancer but the treating physician suspected possible inflammation. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: April 14, 2026 (Form 8-K, Item 8.01).
• Product referenced: CyPath® Lung — a noninvasive sputum‑based diagnostic test.
• Clinical context: used to guide management of a patient with a suspicious pulmonary nodule when imaging and risk models suggested high cancer probability but inflammation was suspected.
• Disclosure: press release attached as Exhibit 99.1 to the 8-K (Item 9.01 lists exhibits).

Why It Matters

• The filing documents a real‑world clinical example of CyPath® Lung being used to inform physician decision‑making, which the company is publicizing via its press release. The 8-K does not include financial results, commercial agreements, regulatory approvals, or broader clinical trial data—only the described case study and the press release attachment. Investors should view this as an informational disclosure about clinical use; any implications for revenue or market adoption are not detailed in the filing.